Boehringer Ingelheim has strengthened its position oncology department with the goal of finding a cure for cancer, a business in which, among others, other large pharmaceutical companies such as Novartis, MSD or Roche are immersed. The latest step in this regard by the German pharmaceutical company was an alliance with CBmed GmbH Center for Biomarker Research in Medicine (CBmed). The goal of this agreement is to apply translational medicine approaches to develop first-in-class drugs to treat a range of cancer types.
Collaboration with CBmed will allow Boehringer Ingelheim to identify and check biomarkers for projects in your portfolio anti-cancer products, for the purpose of therapy, identification of new indications and patient selection. This will lead to the German company accelerating its cancer research as well as expanding its portfolio. oncology products.
There has been talk for some time about the enormous benefits that precision medicine brings to the field of oncology. Boehringer Ingelheim says that while this new approach to medicine does offer greater potential to treat more types of cancer, 97 out of every 100 clinical trials test compounds for a specific indication. failed to demonstrate significant benefit for cancer patients.
97 out of 100 clinical trials failed to demonstrate significant benefit.
These failures are due primarily to a lack of knowledge about how and why cancer treatments kill cancer cells directly or through activation of the immune system and which cancer patients may benefit from specific treatments. Translational medicine addresses this problem by identifying biomarkers to assess the therapeutic effect of treatments and creating a deep understanding of disease pathology.
CBmed is a pioneer in the field of translational medicine research and currently maintains close collaboration with the medical universities of Graz and Vienna. This company created multi-omics technology platform uniquely designed to accelerate the discovery of new biomarkers. It combines in-house capabilities in molecular pathology, cancer immunobiology and data science with scientific and medical expertise and access to comprehensive biobanking. These include Europe’s largest biobank, located in Graz, with seven million patient samples, and BBMRI-ERIC, the largest biobank network in the world, with 60 million patient samples.
The new alliance between the two companies will be implemented gradually. Thus, as a first measure, “CBmed will, from April 2024, expand its research infrastructure in Graz with specialized laboratories and offices, as well as up to 30 experienced scientists and medical translators, focused on the new partnership with Boehringer,” as explained by the CEO of CBmed : Robert Lobnig.
The company’s commitment to the fight against cancer is clear. The pharmaceutical company says it takes a thorough and broad approach to some of the most challenging, but potentially most impactful areas of oncology research. “We have developed strong portfolio of proprietary clinical assets and under license or in combination with a wide range of modes of action, including experimental therapies targeting cancer cells and immuno-oncology. It is a judicious combination of these approaches that can bring the greatest benefit to cancer patients.
Net sales of human health the German company grew by 11.3% and reached 9.6 billion euros. in the first half of 2022. This was mainly done on the initiative of the family. Gardenwhich is used to treat type 2 diabetes in adults and has recently been approved by the EU for patients with Chronic kidney disease (ERC), with 3.5 billion euros. The same thing happened with respiratory drugs. Ofeevindicated in adults for the treatment of idiopathic pulmonary fibrosis (IPF), costing €1.7 billion.
Boehringer Ingelheim has committed to spending €25 billion on research and development over the next five years.
The company has committed to allocate 25,000 million euros for research and development, in addition to another 7 billion euros for new production technologies during the next five years.
What is most notable in the field of oncology is that its agonist MDM2-p53 Brigimadlin have begun a pivotal study to treat dedifferentiated liposarcoma, a rare cancer for which there are currently few therapeutic options. Clinical development of two other investigational drugs (zongertinib, also known as BI 1810631 and BI 764532) oncology productswas accelerated due to early positive clinical data.
Finally, the company also plans to enter the obesity market in collaboration with Zealand Pharma through development Survodutid.
Bonoloto The result of the Bonoloto draw today, Saturday, October 5, 2024, was the numbers…
The Halo Infinite experience is about to change with the arrival of peculiarity what the…
It is convenient to explain, point by point, perhaps the strangest game in recent years…
The Menendez brothers were convicted of perpetual apostasy after discovering their parents escaped the abuse.…
The Israeli military claimed to have killed two senior Hamas officials in separate attacks on…
A new study from the University of Turku (Finland), compiled by Ep, found that Reducing…